Canada: Confronting The Opioid Crisis

Last Updated: December 8 2016
Article by Kathryn Frelick

Opioid misuse and abuse is a serious societal problem and public health threat. Globally, Canada is second only to the United States in per capita consumption of prescription opioids; painkillers such as oxycodone, hydrocodone, fentanyl and morphine. This has led to a significant increase in opioid-related deaths and a critical need for addiction treatment services across the country.

The problem has been amplified by the diversion of prescription fentanyl products (primarily transdermal patches), as well as the influx of pharmaceutical grade fentanyl into the illicit drug market which has led to an alarming number of deaths and overdoses across Canada, giving rise to what has been coined the opioid crisis. It has been reported that in Ontario alone, more than 700 people died from opioid-related overdoses in 2014.

Fentanyl is a powerful synthetic opioid analgesic that is similar to morphine but is 50 to 100 times more potent. Even when manufactured in controlled settings, its chemical composition renders it highly toxic and addictive. Where the drug is manufactured in uncontrolled facilities, a slight change in the chemical composition of fentanyl can cause its toxicity to increase, which can have fatal results.

The federal and provincial governments have taken a number of actions to address these issues. Earlier this year, naloxone, which is used as an overdose antidote, was made more widely available to first responders and the public. In July, the federal minister of Health signed an interim order allowing naloxone nasal spray to be sold in Canada and announced Health Canada's Action Plan on Opioid Abuse.

The federal government is looking at issues such as unauthorized importation, illegal use, controlled use and proactive measures to lessen the number of opioid-related incidents nationally. This includes legislative amendments to the Controlled Drugs and Substances Act (CDSA) which would place six chemicals used in the production of fentanyl on the schedule of substances prohibited by the CDSA and Precursor Control Regulations. The federal government hopes to better control, monitor and prohibit the unauthorized importation and exportation of opioids.

In October, the province of Ontario announced its "opioid strategy." The strategy aims to lessen the harm of opioids in the community through regulation, surveillance and reporting. It builds on the Narcotics Safety and Awareness Act, 2010 which allowed for enhanced data collection and monitoring of opioids and the Safeguarding our Communities Act, 2015 which places stricter controls on the prescribing and dispensing of fentanyl patches. For example, as of Oct. 1, patients are required to return used patches to their pharmacy before more can be dispensed.

Other strategies include the delisting of high-strength formulations of long-acting opioids from the Ontario Drug Benefit Formulary and the introduction of Suboxone as a first-line treatment for opioid addiction. Unlike methadone which can only be prescribed by physicians who have special authorization, Suboxone may be prescribed by primary care physicians. In addition, the province announced plans to create or enhance 17 chronic pain clinics.

The overuse of opioids is a pervasive problem that cannot be resolved simply by increasing regulation. Underpinning these issues are concerns about the indiscriminate or improper prescription of opioids, particularly for chronic non-cancer pain. Physicians have come under a high level of scrutiny for their prescribing practices, including the assessment and monitoring of patients, use of opioid misuse screening tools and treatment agreements and consultation and collaboration with other healthcare providers and specialists. The College of Physicians and Surgeons of Ontario is investigating over 80 doctors after the province's narcotics monitoring system flagged physicians with unusually high prescribing practices. The college has yet to consider the accuracy of the data and to assess whether physician practices meet acceptable standards, policies and guidelines.

The controversy attached to opioid prescribing has led to some physicians adopting a "no narcotics" prescribing practice. This can also be problematic as it may result in inadequate or ineffective treatment for pain. Patients are entitled to receive safe and effective pain management, whether for chronic pain or palliative care. In this respect there has been some backlash toward the opioid strategy by physicians who fear that some of the new strategies, for example the delisting of high dose opioids, may negatively affect how palliative care patients are treated, or may cause physicians to prescribe a greater amount of low-dose opioids to assist in proper treatment.

These are extremely complex, multi-faceted issues that require a highly co-ordinated response. Legislative changes alone will not address the problem, but are only a start.

Previously published in The Lawyers Weekly - November 2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Kathryn Frelick
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions